2 completed, 1 no longer available, 1 recruiting. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Super-refractory Status Epilepticus: new trials by email Literature Review of Super-refractory Status Epilepticus trials Research Report on Super-refractory Status Epilepticus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KD Treatment for Super-refractory Status Epilepticus the ketogenic diet, Standard Medical Therapy - Super-refractory Status Epilepticus | Not applicable | Recruiting | Xuanwu Hospital, Beijing | 84 | 2025-10-20 | 2026-05-15 |
| A Study With SAGE-547 for Super-Refractory Status Epilepticus SAGE-547, Placebo - Super-Refractory Status Epilepticus | Phase 3 | Completed | Supernus Pharmaceuticals, Inc. | 132 | 2015-06-01 | 2025-10-14 |
| Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus SAGE-547 - Super-refractory Status Epilepticus | Phase 1 / Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 25 | 2014-03-21 | 2025-09-15 |
| An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus SAGE-547 - Super-Refractory Status Epilepticus | No longer available | Supernus Pharmaceuticals, Inc. | 2025-09-15 |
Status Epilepticus (2) · Encephalitis (1)
Nervous System Diseases (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Seizures (2) · Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Neuroinflammatory Diseases (1)
brexanolone (3)
Supernus Pharmaceuticals, Inc. (3) · Xuanwu Hospital, Beijing (1)
United States (2) · Austria (1) · Canada (1) · China (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Serbia (1) · Spain (1)
Eric Rosenthal, MD (1) · Henrikas Vaitkevicius, MD (1) · Mark Wainwright, MD, PhD (1) · Robert Lasser, MD, MBA (1)